DC-CIK免疫治疗联合化疗对晚期乳腺癌患者的效果  

Effect of DC-CIK Immunotherapy Combined with Chemotherapy in Patients with Advanced Breast Cancer

作　　者：张道全[1] 蒋雪超[1] 单新芳 Zhang Daoquan;Jiang Xuechao;Shan Xinfang(Binzhou Central Hospital,Binzhou 251700,Shandong Province,China)

机构地区：[1]滨州市中心医院,山东滨州251700

出　　处：《中国社区医师》2023年第20期58-60,共3页Chinese Community Doctors

摘　　要：目的:研究树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)免疫治疗联合化疗对晚期乳腺癌患者的临床效果。方法:选取2017年11月—2019年5月滨州市中心医院收治的晚期乳腺癌患者56例作为研究对象,随机分为试验组与对照组,各28例。对照组接受常规化疗措施,试验组在对照组基础上应用DC-CIK免疫治疗。对比两组免疫指标、治疗效果。结果:试验组CD3^(+)、CD3^(+)/CD4^(+)、NK细胞水平高于对照组,CD3^(+)/CD8^(+)水平低于对照组,差异有统计学意义(P<0.05)。试验组治疗总有效率高于对照组,差异有统计学意义(P=0.005)。结论:晚期乳腺癌采用DC-CIK免疫治疗联合化疗的效果显著,可改善免疫指标。Objective:To study the clinical effect of dendritic cells-cytokine-induced killer cells(DC-CIK)immunotherapy combined with chemotherapy in patients with advanced breast cancer.Methods:From November 2017 to May 2019,56 patients with advanced breast cancer admitted to Binzhou Central Hospital were selected as the study subjects.They were randomly divided into experimental group and control group,with 28 patients in each group.The control group was given conventional chemotherapy measures,and the experimental group was given DC-CIK immunotherapy on the basis of the control group.The immune indexes and treatment effects in the two groups were compared.Results:The CD3^(+),CD3^(+)/CD4^(+)and NK cell levels in the experimental group were higher than those in the control group,and the CD3^(+)/CD8^(+)levels in the experimental group were lower than those in the control group,and the difference was statistically significant(P<0.05).The total effective rate of treatment in the experimental group was higher than that in the control group,and the difference was statistically significant(P=0.005).Conclusion:DC-CIK immunotherapy combined with chemotherapy has a significant effect in patients with advanced breast cancer and can improve immune index.

关 键 词：晚期乳腺癌 DC-CIK免疫治疗 化疗 

分 类 号：R737.9[医药卫生—肿瘤]